Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Castle Biosciences, Inc. (CSTL) had Consolidated Net Income/Loss of $-0.50M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$83.04M |
|
$-0.50M |
|
$18.70M |
|
$64.34M |
|
$89.85M |
|
$-6.80M |
|
$6.42M |
|
$-0.39M |
|
$-0.39M |
|
$-0.50M |
|
$-0.50M |
|
|
Consolidated Net Income/Loss |
$-0.50M |
$-0.50M |
|
$-6.80M |
|
$-3.89M |
|
29.07M |
|
29.07M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$357.57M |
|
$84.89M |
|
$205.22M |
|
$562.79M |
|
$55.31M |
|
$10.39M |
|
$40.43M |
|
$95.74M |
|
$467.05M |
|
$365.20M |
|
$467.05M |
|
29.16M |
|
| Cash Flow Statement Financials | |
$37.42M |
|
$-69.20M |
|
$-2.37M |
|
$119.71M |
|
$85.56M |
|
$-34.15M |
|
$34.49M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.47 |
|
-- |
|
-- |
|
0.02 |
|
0.02 |
|
77.48% |
|
-8.19% |
|
-8.19% |
|
-- |
|
-0.46% |
|
-0.60% |
|
$8.62M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
2.16 |
|
1.68 |
|
53.63 |
|
-0.11% |
|
-0.14% |
|
-0.09% |
|
-0.10% |
|
$16.02 |
|
$0.30 |
|
$1.29 |
|